Monzosertib for blood cancers that returned or didn't respond to treatment
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new drug called monzosertib for people with blood cancers like AML or MDS that have not responded to standard treatments. The goal is to see if the drug can help control the disease and what side effects it may cause.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and have AML, MDS, or CMML that has come back or hasn't improved after standard treatment.
- You have a certain level of day-to-day activity (ECOG score 0 to 2) — meaning you are up and about at least half the day.
- Your liver and kidneys are working well enough (based on blood tests).
- If you are of childbearing age, you agree to use effective birth control during the trial and for at least 3 months after.
- If you had a stem cell transplant, you have recovered fully and are off most immune-suppressing medicines.
- You don't have an uncontrolled infection, serious heart rhythm problems, or other severe medical conditions that would make participation unsafe.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests a new drug called STX-0712 for people with certain types of blood cancers (CMML or AML) that have not responded to standard treatments. The goal is to see if the drug is safe and can help shrink or control the cancer.
This trial tests a new drug called cirtuvivint, given alone or with another drug (ASTX727), for people with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) that has come back or not responded to treatment, and for people with high-risk MDS who have not been treated before. The goal is to see if these combinations work better than current options.
This trial tests two targeted drugs, ziftomenib and quizartinib, together for people with a certain type of acute myeloid leukemia (AML) that has come back or not responded to treatment. The goal is to find the best dose and see if the combination helps.
This Phase 1/2 trial tests a combination of medicines (decitabine/cedazuridine, venetoclax, and ivosidenib or enasidenib) in people with acute myeloid leukemia (AML) that has come back or hasn’t responded. It may help control the leukemia by targeting cancer cells and specific genetic changes in the leukemia.
This trial tests a combination treatment (chemo drugs plus a growth-factor medicine) for people newly diagnosed with acute myeloid leukemia (AML) or certain high-risk myelodysplastic syndromes (MDS). It may help by targeting cancer cells in the blood and bone marrow and improving remission chances.
This study tests an experimental drug called S241656, either alone or with another medication, for people with certain blood cancers (AML, MDS/AML, or CMML) that haven't responded to standard treatments. The goal is to see if the drug is safe and effective in shrinking or controlling the cancer.
Hear when a new Acute Myeloid Leukemia (AML) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.